Neuronetics Announces Proposed Public Offering of Common Stock
Key Highlights
- ➤Neuronetics (STIM) launches underwritten public offering; size and terms remain undisclosed
- ➤Underwriters receive option for up to 15% additional shares at offering price
- ➤Perceptive amendment requires at least $15 million prepayment plus fees by November 30
- ➤Reduced revenue covenants could resolve Neuronetics’ disclosed going-concern risk
- ➤Offering proceeds are intended partly to prepay Perceptive Facility term loans
MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock in the proposed offering will be sold by Neuronetics. In addition, Neuronetics intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Get started
Create a free account to read the full story.